Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Virtual Screening and Experimental Validation Identify Novel Inhibitors of the Plasmodium falciparum Atg8-Atg3 Protein-Protein Interaction.

Hain AU, Miller AS, Levitskaya J, Bosch J.

ChemMedChem. 2016 Apr 19;11(8):900-10. doi: 10.1002/cmdc.201500515. Epub 2016 Jan 8.

PMID:
26748931
2.

Inhibition by stabilization: targeting the Plasmodium falciparum aldolase-TRAP complex.

Nemetski SM, Cardozo TJ, Bosch G, Weltzer R, O'Malley K, Ejigiri I, Kumar KA, Buscaglia CA, Nussenzweig V, Sinnis P, Levitskaya J, Bosch J.

Malar J. 2015 Aug 20;14:324. doi: 10.1186/s12936-015-0834-9.

3.

Flow Cytometry Based Detection and Isolation of Plasmodium falciparum Liver Stages In Vitro.

Dumoulin PC, Trop SA, Ma J, Zhang H, Sherman MA, Levitskaya J.

PLoS One. 2015 Jun 12;10(6):e0129623. doi: 10.1371/journal.pone.0129623. eCollection 2015.

4.

Priming of CD8(+) T Cell Responses to Liver Stage Malaria Parasite Antigens.

Corradin G, Levitskaya J.

Front Immunol. 2014 Nov 5;5:527. doi: 10.3389/fimmu.2014.00527. eCollection 2014. Review.

5.

Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the medicines for Malaria Venture Malaria Box active in blood and liver stage Plasmodium falciparum parasites.

Hain AU, Bartee D, Sanders NG, Miller AS, Sullivan DJ, Levitskaya J, Meyers CF, Bosch J.

J Med Chem. 2014 Jun 12;57(11):4521-31. doi: 10.1021/jm401675a. Epub 2014 May 19.

6.

Dynamics of the major histocompatibility complex class I processing and presentation pathway in the course of malaria parasite development in human hepatocytes: implications for vaccine development.

Ma J, Trop S, Baer S, Rakhmanaliev E, Arany Z, Dumoulin P, Zhang H, Romano J, Coppens I, Levitsky V, Levitskaya J.

PLoS One. 2013 Sep 25;8(9):e75321. doi: 10.1371/journal.pone.0075321. eCollection 2013.

7.

The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes.

Carlson LM, De Geer A, Sveinbjørnsson B, Orrego A, Martinsson T, Kogner P, Levitskaya J.

Oncoimmunology. 2013 Mar 1;2(3):e23618.

8.

Deficiency of a Niemann-Pick, type C1-related protein in toxoplasma is associated with multiple lipidoses and increased pathogenicity.

Lige B, Romano JD, Bandaru VV, Ehrenman K, Levitskaya J, Sampels V, Haughey NJ, Coppens I.

PLoS Pathog. 2011 Dec;7(12):e1002410. doi: 10.1371/journal.ppat.1002410. Epub 2011 Dec 8.

9.

Syntaxin 11 marks a distinct intracellular compartment recruited to the immunological synapse of NK cells to colocalize with cytotoxic granules.

Dabrazhynetskaya A, Ma J, Guerreiro-Cacais AO, Arany Z, Rudd E, Henter JI, Karre K, Levitskaya J, Levitsky V.

J Cell Mol Med. 2012 Jan;16(1):129-41. doi: 10.1111/j.1582-4934.2011.01280.x.

10.

B cell receptor triggering sensitizes human B cells to TRAIL-induced apoptosis.

Guerreiro-Cacais AO, Levitskaya J, Levitsky V.

J Leukoc Biol. 2010 Nov;88(5):937-45. doi: 10.1189/jlb.0510246. Epub 2010 Aug 13.

PMID:
20709941
11.

Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes.

Hallermalm K, Seki K, De Geer A, Motyka B, Bleackley RC, Jager MJ, Froelich CJ, Kiessling R, Levitsky V, Levitskaya J.

J Immunol. 2008 Mar 15;180(6):3766-74.

12.

Differentiation induced by physiological and pharmacological stimuli leads to increased antigenicity of human neuroblastoma cells.

Carlson LM, Påhlman S, De Geer A, Kogner P, Levitskaya J.

Cell Res. 2008 Mar;18(3):398-411. doi: 10.1038/cr.2008.27.

13.

Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma.

De Geer A, Carlson LM, Kogner P, Levitskaya J.

Cancer Immunol Immunother. 2008 May;57(5):731-43. Epub 2007 Oct 26.

PMID:
17962944
14.

Cytotoxic T lymphocytes induce caspase-dependent and -independent cell death in neuroblastomas in a MHC-nonrestricted fashion.

De Geer A, Kiessling R, Levitsky V, Levitskaya J.

J Immunol. 2006 Dec 1;177(11):7540-50.

15.
16.

Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells.

Vertuani S, Dubrovska E, Levitsky V, Jager MJ, Kiessling R, Levitskaya J.

Cancer Immunol Immunother. 2007 Feb;56(2):193-204. Epub 2006 Jun 3.

PMID:
16752155
17.

Mature dendritic cells induce tumor-specific type 1 regulatory T cells.

Lundqvist A, Palmborg A, Pavlenko M, Levitskaya J, Pisa P.

J Immunother. 2005 May-Jun;28(3):229-35.

PMID:
15838379
18.

Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes.

Hallermalm K, De Geer A, Kiessling R, Levitsky V, Levitskaya J.

Cancer Res. 2004 Sep 15;64(18):6775-82.

19.

Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues.

Vertuani S, Sette A, Sidney J, Southwood S, Fikes J, Keogh E, Lindencrona JA, Ishioka G, Levitskaya J, Kiessling R.

J Immunol. 2004 Mar 15;172(6):3501-8.

20.

Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes.

Vertuani S, De Geer A, Levitsky V, Kogner P, Kiessling R, Levitskaya J.

Cancer Res. 2003 Nov 15;63(22):8006-13.

21.

IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.

Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, Rabbani H, Moretta A, Söderström K, Levitskaya J, Kiessling R.

J Clin Invest. 2002 Nov;110(10):1515-23.

22.

HLA expression in uveal melanoma: there is no rule without some exception.

Jager MJ, Hurks HM, Levitskaya J, Kiessling R.

Hum Immunol. 2002 Jun;63(6):444-51. Review.

PMID:
12039519
23.

Modulation of intracellular Ca(2+) concentration by vitamin B12 in rat thymocytes.

Sukocheva OA, Abramov AY, Levitskaya JO, Gagelgans AI, Carpenter DO.

Blood Cells Mol Dis. 2001 Sep-Oct;27(5):812-24.

PMID:
11783944
24.
25.

Supermotif peptide binding and degeneracy of MHC: peptide recognition in an EBV peptide-specific CTL response with highly restricted TCR usage.

Levitsky V, Liu D, Southwood S, Levitskaya J, Sette A, Masucci MG.

Hum Immunol. 2000 Oct;61(10):972-84.

PMID:
11082510
27.

Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.

Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG.

Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12616-21.

28.

Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.

Frisan T, Zhang QJ, Levitskaya J, Coram M, Kurilla MG, Masucci MG.

Int J Cancer. 1996 Oct 9;68(2):251-8.

30.

Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.

Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG.

Nature. 1995 Jun 22;375(6533):685-8.

PMID:
7540727

Supplemental Content

Loading ...
Support Center